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A Revisit to the Pretargeting
Concept—A Target Conversion
Guozheng Liu*
Department of Radiology, University of Massachusetts Medical School, Worcester, MA, United States
Pretargeting is often used as a tumor targeting strategy that provides much higher tumor
to non-tumor ratios than direct-targeting using radiolabeled antibody. Due to the multiple
injections, pretargeting is investigated less than direct targeting, but the high T/NT ratios
have rendered it more useful for therapy. While the progress in using this strategy for
tumor therapy has been regularly reviewed in the literature, this review focuses on the
nature and quantitative understanding of the pretargeting concept. By doing so, it is
the goal of this review to accelerate pretargeting development and translation to the
clinic and to prepare the researchers who are not familiar with the pretargeting concept
but are interested in applying it. The quantitative understanding is presented in a way
understandable to the average researchers in the areas of drug development and clinical
translation who have the basic concept of calculus and general chemistry.
Keywords: pretargeting, target conversion, tumor accumulation, quantitative correlation, semi-empirical model
INTRODUCTION
The pretargeting strategy (hereafter referred to as pretargeting) has been investigated for 30-odd
years since its introduction to the field of radiotherapy (Reardan et al., 1985; Goodwin et al., 1986;
Hnatowich et al., 1987). Because of its multiple injections, pretargeting is less investigated than
the direct-targeting in which the effecting group is attached directly to the targeting antibody.
Persistent efforts of several groups have advanced this strategy to clinic trials and the progress has
been regularly updated (Goodwin, 1995; Goodwin and Meares, 1997; Barbet et al., 1999; Chang
et al., 2002; Sharkey and Goldenberg, 2005, 2006, 2008, 2011; Goldenberg et al., 2006, 2008, 2012;
Sharkey et al., 2007, 2010, 2012a,b; Goldenberg and Sharkey, 2010; Huang et al., 2011; Knight
and Cornelissen, 2014; Kraeber-Bodéré et al., 2015; Larson et al., 2015; Bartholomä, 2018). This
review focuses on understanding the pretargeting concept in a more quantitative way, in a hope to
accelerate its development and translation to the clinic.
THE NATURE OF PRETARGETING
Pretargeting prelocalizes an antitumor antibody into the tumor before injecting a small radiolabeled
effector to recognize and specifically bind to it. The effector is excreted rapidly if not bound to
the antibody. Pretargeting is widely viewed as a separation of tumor targeting of the antibody
(pretargeting process) from the radioactivity administration to avoid the radiation exposure during
the long process of antibody targeting (Goodwin, 1995; Goodwin and Meares, 1997). Figure 1
demonstrates the pretargeting process and schematically illustrates the tumor and blood curves
of a labeled antibody in a direct-targeting strategy and a effector in a pretargeting process
using that antibody. It helps to appreciate how pretargeting improves the tumor to blood
ratio (and the ratios of the area-under-the radioactivity-curves, i.e., the therapeutic indexes)
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FIGURE 1 | A typical pretargeting procedure and a schematic demonstration of the antibody concentration (in %ID/g) and the effector radioactivity (also in %ID/g) in
the tumor and blood. Injection of the pretargeting antibody converts the antigen into a secondary target that binds the effector and injection of the effector allows the
label to accumulate into tumor as illustrated in the pinhole SPECT image. In the schematic demonstration, the scales of antibody concentration and the effector
radioactivity are adjusted to allow the curves for superimposition after the circulating free effector is cleared. It shows the concept of the in vivo labeling of the antibody
and enables a better appreciation that the ratio of the tumor/blood area-under-curve for the effector radioactivity is much larger than that of the antibody.
(Sung and van Osdol, 1995; Magnani et al., 1996; Pagel et al.,
2003; Subbiah et al., 2003; Karacay et al., 2005; Sharkey et al.,
2005). The effector curve (%ID/g) rapidly superimposes on
that of the direct-targeting labeled antibody. It seems like
the pretargeting antibody can be labeled in vivo, if assuming
the labeled antibody and the pretargeting antibody behaves
identically. However, it does not mean the percent tumor
accumulation of the effector in a pretargeting setting is the same
as that of the antibody in the direct-targeting setting. In fact,
due to rapid clearance of the effector, its tumor accumulation is
much lower than that of the antibody. The scales of the antibody
concentration and the effector concentration (proportional to the
radioactivity) are not the same and have been adjusted for the
superimposition after the free effector is excreted.
We can also view pretargeting as a strategy to convert natural
antigens into a secondary target specific for the small effector.
This understanding helps to quantitatively comprehend how
the tumor accumulation (%ID/g) of the effector depends on
the antibody dosage, pretargeting interval (the time between
the injections of the antibody and the effector), effector dosage,
detection time (the time after radioactivity injection), and
the properties of the effector, tumor, and tumor host. A
natural question from this understanding is the necessity of the
conversion. If a small targetingmolecule is available that provides
equally excellent target accumulation and comparable target to
non-target (T/NT) ratios to that of the radiolabeled effector, the
answer is no. Nevertheless, chances are such a small targeting
molecule (or its target) may not be available. It is not easy to
design a structure to provide both a high binding affinity to
the tumor and a low normal tissue background simultaneously
(Haberkorn et al., 2017; Kopka et al., 2017). Although most
nuclear medicine imaging agents are small labeled molecules,
few generate high target to non-tumor ratios and thus most
are not satisfactory for tumor therapy (Herrmann et al., 2017;
Bartholomä, 2018; Tsai and Wu, 2018). Also, a small targeting
agent is specific for one target but an established pretargeting
system can be applied to many antibodies that target different
antigens.
We note that the target conversion comes at some expenses.
In addition to the complexity of 2 injections, as a side effect the
residual pretargeting antibody in the circulation binds the later-
injected effector. In other words, pretargeting unfavorably creates
an undesired low level of secondary targets in the circulation.
Waiting for a period to allow the pretargeting antibody to be
excreted from the circulation and optimizing the effector dosage
canmitigate this side effect, but it is only a compromised solution.
Use of a clearing agent as an additional injection would be
more effective and may be a real solution. When the tumor
accumulation is close to the maximum, injection of the clearing
agent will bind and clear the residual circulating pretargeting
antibody into liver. In the section of “3-Step pretargeting,” we will
discuss this in more detail. If the effector is properly dosaged, the
blood and normal tissue effector levels will be minimal while the
tumor accumulation (%ID/g) will not be compromised by use of
a clearing agent. As a result, much higher target to non-tumor
(also abbreviated as T/NT) ratios can be provided to allow for a
higher radioactivity dosage and more effective radiotherapy.
DIFFERENT PRETARGETING
MECHANISMS
There are several mechanisms for pretargeting, i.e., several
different recognition pairs of secondary target (on the
antibody)/effector. At least four mechanisms have been
employed, namely the bispecific antibody/hapten(Reardan
et al., 1985), (strept)avidin/biotin(Hnatowich et al., 1987),
DNA/cDNA analogs(Kuijpers et al., 1993), and in vivo click
reaction(Agard et al., 2004). These mechanisms each have their
own advantages, but their nature and function are the same.
They convert the primary natural antigens to a secondary target
for a small effector, to allow for a low normal tissue background
and high T/NT ratios. Figure 2 illustrates the final structures of
the linkages between the labels and antigens on the tumor cell
surface. We note that the entire structure may internalize after
binding to the tumor.
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FIGURE 2 | Four recognition mechanisms for pretargeting, namely (A) bispecific antibody/bivalent hapten, (B) streptavidin (SAv)/biotin, (C) DNA/cDNA analogs, and
(D) in vivo clicking reaction (shown as an example is the reaction between cycloctene and tetrazine). Ag, antigen; Ab, antibody; SAv, streptavidin.
The bispecific antibody/hapten mechanism was first proposed
(Reardan et al., 1985). It initially experienced a low tumor
retention due to the low binding affinity of the effector to the
secondary target. The effector binding was later improved by
use of bivalent haptens (Barbet et al., 1999). Although it has
not become a standard of care at this time, this mechanism is
continually being tried in the clinic or investigated preclinically
(Goldenberg et al., 2006, 2012; Schoffelen et al., 2013, 2014;
Bodet-Milin et al., 2016; Cheal et al., 2016, 2017). For example,
Dr Larson’s group recently reported a therapeutic study using
the DOTA-PRIT approach, in which a bispecific antitumor
antibody engineered by Dr. Wittrup’s lab was used to bind
the 177Lu-DOTA effector (Cheal et al., 2017). The preclinical
success with tumor cure in mice may have benefited from
the excellent pharmacokinetics of the 177Lu-DOTA, the highly
efficient clearing mechanism, the long half-life of the 177Lu, and
the multiple therapeutic cycles.
The (strept)avidin/biotin mechanism was proposed almost
as early as the bispecific antibody/hapten mechanism. In the
beginning, it attracted more attention probably because of the
high affinity of the recognition pair (Hnatowich et al., 1987;
Green, 1990). Prior to streptavidin, avidin was tested. But as
we recently demonstrated (Dou et al., 2014a), after attaching to
the antibody and injecting to animal or human body it drags
the antibody into liver too rapidly. Thus, the chance of pre-
localization of the secondary avidin target in the tumor was
severely compromised. The later-used streptavidin has another
problem of immunogenicity (Knox et al., 2000). In addition,
streptavidin-antibody internalizes more rapidly and thus reduces
the number of binding sites for the labeled biotin effector
(Casalini et al., 1997; Muzykantov et al., 1999). Nevertheless,
there continue to be investigations testing its clinical utility to
target hematological malignancies (Frost et al., 2015).
The DNA/cDNA mechanism was introduced in 1993
(Kuijpers et al., 1993), much later than the two above-mentioned
mechanisms. The initial in vitro test was successful but natural
DNAs are not stable in vivo. The in vivo success was largely
due to the advent of stable synthetic DNA analoges. The first
successes in solid tumor targeting were achieved by use of
the phosphorodiamidate morpholino oligomers (MORFs) (Liu
et al., 2002b), although peptide nucleic acids (PNAs) were also
considered (Rusckowski et al., 1997). Both MORFs and PNAs
do not enter cells by themselves, excrete rapidly into urine and
have no significant immunogenic response or obvious toxicity
(Crooke, 1997). Our choice of MORFs was only based on
their better solubility, slightly lower liver accumulation, and
easier availability to us (Mang’era et al., 2001). MORF/cMORF
pretargeting has been very successful preclinically for both
imaging and therapy (Liu et al., 2006, 2008a, 2010a,c, 2011,
2012; Liu, 2017). Very recently, a Sweden group has achieved
similar successes using the PNAs (Westerlund et al., 2015, 2018;
Honarvar et al., 2016; Altai et al., 2017).
The in vivo click reactions make the most recent recognition
mechanism and currently are under active investigation (Agard
et al., 2004; Chang et al., 2010; Rossin et al., 2010, 2013; Zeglis
et al., 2013; Keinänen et al., 2017; Membreno et al., 2018; Meyer
et al., 2018; Shi et al., 2018). The Staudinger reactions between
phosphines and azides, the strain-promoted cycloadditions, and
the inverse electron-demand Diels-Alder (IEDDA) reactions
have been considered for recognizing biomolecule (Agard et al.,
2004; Carroll et al., 2013; Knight and Cornelissen, 2014). The
IEDDA reactions are compatible to the in vivo environment.
In theory, The formation of a covalent link between the
pretargeted antibody and the effector should favor the effector
retention in tumor. However, it is not clear whether this is
crucial because excellent tumor retention has been achieved
using each of the above-mentioned mechanisms. When the
affinity between the antibody and effector is at or higher than
∼ 10−14 M, retention seems not an issue. Dr. Meares’s group
previously incorporated an in situ covalent bond formation into
the bispecific antibody/hapten mechanism but did not observe
significant improvement in terms of tumor accumulation (Butlin
and Meares, 2006; Corneillie et al., 2006). There is a kinetic
model reporting that a higher binding affinity after reaching a
certain level (∼10−14 M)will not significantly improve the tumor
accumulation (Orcutt et al., 2011).
Another potential advantage of this new in vivo click
pretargeting mechanism may be its “bioorthogonal” nature,
i.e., natural absence in vivo and non-interference with the
in vivo biological process (Nwe and Brechbiel, 2009). In
fact, non-interference of the in vivo biochemical processes
outside of the cells is a prerequisite for pretargeting. For
example, the streptavidin/biotin recognition mechanism is less
used because streptavidin triggers immune response, binds
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the endogenous biotin, and intensifies antibody internalization.
However, there is no evidence for the bispecific antibody/hapten
and DNA/cDNA mechanisms to disturb the in vivo biological
processes. The haptens do not exist in vivo and do not target
endogenous receptors. After internalization, the metal-chelate
haptens residualize but that is an advantage for retention (Larson
et al., 2015). Similar internalization would also happen for in
vivo click pretargeting. The DNA/cDNA mechanism does not
interfere with the biological processes outside of the cells either.
There is no or minimal DNA or RNA sequence outside of the
cells. The cDNA analog effector binds the DNA analog-antibody
outside of the cells and on the cell surface by forming a duplex
bond. In this case even if internalization happens (although little
is known about their fate), nether the cDNA analog effector nor
the DNA analog secondary target would bind the DNA or RNAs
in the cells. Thus, both would not be interfering with the inside
biochemical process. The DNA analog-antibody, if not picking
up an effector and internalizing itself, does have a chance to bind
the DNA or RNA inside of the cells. But if so, that would be a
huge advantage. Researchers in other fields have long desired to
send DNA analogs into cells for gene therapy (Olkkonen et al.,
2018; Rangasamy et al., 2018).
3-STEP PRETARGETING—A
MODIFICATION WITH ON-DEMAND RAPID
CLEARANCE OF THE PRETARGETING
ANTIBODY
As said above, one expense for converting the natural antigens
to a secondary target is the residual circulating secondary target.
Injection of a clearing agent when the tumor accumulation of
the antibody is close to the maximum can effectively address this
issue (Goodwin et al., 1984). This 3-step modified pretargeting
was considered at the early stage of the pretargeting concept and
had been used in the clinical trial of the SAv/biotin recognition
mechanism (Knox et al., 2000). A clearing agent has so far not
considered in the clinical trial of the bispecific antibody/hapten
mechanism probably to reduce complexity (Goldenberg et al.,
2012). However adding a clearing step is crucial for therapy
(Liu, 2016), and researchers have considered incorporation of a
clearance step into this mechanism (Mirallié et al., 2005; Cheal
et al., 2016, 2017).
Discussion of different clearing agents is out of the scope
of this review, but we want to emphasize that most clearance
mechanisms utilize the secondary target of the effector. It can
be easily understood that, while the clearing agent binds the
secondary target on the circulating antibody, it would also
consume some of the secondary target localized in tumor. This
will reduce the number of the binding sites for the effector
in the tumor. The net effect is the same as that of antibody
internalization and use of a lower antibody dosage. Nevertheless,
the effect is rarely experienced in the preclinical stage (Sharkey
et al., 1997), because the binding site reduction can be disguised
by the unchanged percent tumor accumulation of effector at low
dosage. We have indicated that the percent tumor accumulation
of the effector (%ID/g or %ID) will not change if a sufficient
number of the binding sites remains in the tumor (Liu et al.,
2010b), Also, it is fortunate that the circulating antibody is more
accessible for the clearing agent than the antibody localized in
tumor.
Preoccupation of the secondary target by the clearing agent
can be avoided by using an additional secondary target. In other
words, we and other have conjugate two secondary targets on to
an antibody, one for the effector and the other for the clearing
agent (Mirallié et al., 2005; Liu et al., 2010b). In this case, although
the clearing agent may still bind the antibody in the tumor, it will
not block the effector accumulation. We have obtained the proof
of the concept using avidin as a model clearing agent. But avidin
is not an ideal clearing agent because it has a too strong clearing
power that leads to insufficient clearance of the antibody deep
in the interstitial space (Dou et al., 2014a). The use of a milder
clearing agent allows for an effective clearance (Cheal et al., 2014).
In addition, there will be a stochastic effect in attaching two
separate groups to an antibody, that generates a small fraction
of undesired effector-binding antibody lacking the group for the
clearing agent. We have developed a strategy to address this issue
by combining the two groups prior to attaching to the antibody
(Dou et al., 2015).
QUANTITATIVE RELATIONSHIPS FOR THE
TUMOR ACCUMULATION AND NORMAL
TISSUE LEVELS OF THE EFFECTOR
Using a small labeled cDNA analog (99mTc-cMORF) as the
effector, we quantitatively investigated the influence of its dosage
on its tumor accumulation in mice pretargeted 48 h earlier with
a MORF-Ab (Liu et al., 2005). The percent accumulation of
the injected effector per gram of tumor (%ID/g) is shown in
Figure 3A. Figure 3B shows the absolute accumulation (ng/g)
converted from the %ID/g. 4 injections of a small dosage are
performed to observe the effect of fractionated injection (the
exact contribution of each dosage increment). The 1st injection
of the effector is given to all the 4 groups, 2nd injection to Groups
2–4, 3rd injection to Groups 3 and 4, and the 4th injection only to
Group 4. All the mice were euthanized 3 h after the last injection.
The injection intervals were set at 1 h apart because we have
investigated the pharmacokinetics of cMORFs and known the
targeting essentially completes in this period.
In Figure 3A, the overall %ID/g of 99mTc-cMORF in tumor
for the first 2 injections are the same, indicating occupation of
some secondary targets in the tumor by the 1st injection does
not impede the accumulation of the 2nd injection. This is the
theoretical base for the tumor accumulation independence to
the target number that we mentioned in the section of “3-Step
pretargeting.” The overall %ID/g for 3 and 4 injections decline.
After converting the %ID/g into the absolute accumulation
(Figure 3B), it clearly indicates that after the 3rd injection the
tumor can no longer take more cMORF effector, suggesting all
the secondary targets have been occupied (saturated). Thus, the
%ID/g before saturation is a constant and at the maximum.
We referred to it as Maximum Percent Tumor Accumulation
(MPTA). The saturation point is at the interception of the two
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FIGURE 3 | The percent (A) and absolute (B) tumor accumulations of a small cMORF against its dosage. The solid lines are obtained from our semi-empirical model
rather than from regression fits.
straight lines in Figure 3B, the perpendicular line crossing the
point of Group 4 and the straight line crossing the first two
data points (Groups 1 and 2). The solid lines in Figure 3A
are converted from the dotted lines in Figure 3B. Without this
saturation theory, it is not possible to draw such a curved line.
We later confirmed this saturation theory in another two studies
(Liu et al., 2007a, 2010c). Dr Larson’s group also observed similar
phenomenon using the bispecific antibody/hapten mechanism,
though obviously the lines would deviate from the experimental
data a little, probably due to the two binging affinities of the
bivalent effector (Cheal et al., 2016).
We have established a semi-empirical tumor accumulation
model to rationalize the above observations (Liu, 2013).
Although there are more sophisticated tumor targeting models
(Wittrup et al., 2012), this semi-empirical model works better
for us. Unlike most compartment kinetic models (Carson, 1996;
Wittrup et al., 2012), we do not need to fit previous experimental
data for parameters required by the model. Instead, we measure
them directly from experimental data. We refer to our model
as a “chemical reactor” model (Figure 4). In other words, we
consider the tumor like a “chemical reactor” and treat the agent
accumulation based on the principle of mass conservation. Like
most compartment models, this model is a lumped model. It
does not differentiate the heterogeneous nature of a tumor but
describes the tumor as a whole. It is just like “a chemical
engineer forget to turn on the agitator” and, although the
reactions inside the reactor is heterogeneous, the principle of
mass conservation still apply. Lumped models are suitable for
the studies that measure lumped properties including tumor
weight, size, and accumulation of the targeting agent. In Figure 4,
the blood flow (inflow) to the tumor is the product of the
cardiac output F and its fraction to the tumor f. The tumor
weight is represented by W, the tumor trapping efficiency of
the targeting agent by E, and the area under the concentration
curve by AUCblood (input function). This model has been used
to guide our optimization of pretargeting regimens (Liu et al.,
2005, 2007b, 2009b; Liu and Hnatowich, 2008; Dou et al.,
2014b).
FIGURE 4 | The “chemical reactor” model showing the inflow and outflow of a
targeting molecule in the tumor (like a chemical reactor). E is the trapping
efficiency of the targeting agent. Its accumulation dQ (ng) = F × f × C (ng/g) ×
E × dt.
When a tumor targeting agent is injected into the circulation,
the blood flow carries the targeting molecules to the tumor. As
shown in Figure 4, a fraction E is trapped there. Based on the
principle of mass conservation, in an infinite small interval dt for
a gram of tumor, the accumulation dQ of a targeting agent that
binds the tumor with infinite affinity is:
dQ (ng/g) = F(mL/Min)× f ×W−1(g)× E× C(
ng
mL
)× dt (Min)
(1)
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whereC is the blood concentration of the targeting agent (ng/mL;
assuming 1mL of blood weighs a gram, the concentration can
also be presented as ng/g). It tells a linear relationship of the
accumulation rate to the blood concentration (C) just like the
one-compartment model does: dQ= k× C× dt (Carson, 1996),
but it further indicates k is related to F, f, W, and E.
Theoretically, starting from the bolus injection, the targeting
continues for an indefinitely long period (∞) and the final
accumulation is (the units will be omitted hereafter unless
necessary):
Q =
∫ t=∞
t=0
F × f ×W−1 × E× C × dt (2)
Dividing both sides of the equation by the injected dosage (in
ng), we have the percent tumor accumulation (PTA) per gram
of tumor:
PTA
(
%ID/g
)
= F × f ×W−1
∫ t=∞
t=0
E× C(%ID/g)blood × dt
(3)
Although in theory tumor accumulation continues for an
infinitely long time, it essentially completes when the time is
sufficiently long, for examples 1 h is enough in mice for the
pretargeting effectors and 2 d for the labeled IgG antibodies.
Tumor Accumulation at Non-Saturating
Dosages
In Figure 3, the first injection does not impede the accumulation
of the second, indicating that before target saturation E for a small
molecule with a very high affinity should be a constant and thus
can be pulled out of the integration. Also shown in Figure 3A is
that in this case the PTA is at the maximum (MPTA, the height of
the perpendicular line):
MPTA
(
%ID/g
)
= F × f ×W−1 × E
∫ t=∞
t=0
C(%ID/g)blood × dt
= F × f ×W−1 × E × AUCblood (4)
We note although this MPTA expression (Equation 4) is derived
from the cMORF tumor accumulation in a pretargeted setting,
it should also apply to direct targeting, because we did not put
any constraint as to whether the target is primary or secondary.
Consistent to the experiences and as taken for granted when
performing a biodistribution assay, the biodistribution of a
labeled compound before saturation is the same regardless of its
dosage, unlike in a block study or using a very large dosage at
which the targets can be saturated.
Equation 4 is of predicting power. In pretargeted mice the
effector binds the secondary target that is converted from an
antigen, but the properties of the antibody specific for the antigen
are not in the equation. We have validated that regardless of
the antibody used, the MPTA is the same (Liu et al., 2008b).
Furthermore, although increasing the dosage of the pretargeting
antibody would increase the number of the secondary target
sites, the number of the target sites is not expressed as a
parameter in Equation 4. Thus, the MPTA will be at the same
value as long as the effector dosage is below the saturation
point (Liu et al., 2007a). For the same reason, increasing the
number of the secondary targets by a so-called “amplification
pretargeting” would neither improve the MPTA. This deduction
rationalizes the previous failure in improvingMPTA by use of the
amplification mechanism (Kassis et al., 1996; He et al., 2004).
Tumor Accumulation at Saturating
Dosages
When the dosage of a targeting agent is above the saturation
point, the conditions for MPTA will no longer exist. The tumor
accumulation will then be dictated by the target number. If one
effector binds one secondary target, the number of target sites
should be equal to the number of effector molecules bound to the
target, therefore
PTAagent
(
%ID/g
)
=
target number per gram of tumor
Number of targeting molecules injected
× 100% (5)
The target number (moles of the secondary target for
pretargeting) per gram of tumor should be the product of the
moles of antibody injected (dosage of antibody Dantibody over its
molecular weightMantibody), the tumor accumulation of antibody
(MPTAantibody in %ID/g), the groups of secondary target per
antibody (gpm), and the fraction of the secondary targets that are
not internalized and still able to bind the effector in the tumor
(α). The number of targeting molecules (moles of the effector)
injected is the effector dosage (Deffector) over its molecular weight
(Meffector). Thus, the percent tumor accumulation of the effector
will be:
PTAeffcetor
(
%ID/g
)
=
Meffector × Dantibody × gpm × α× MPTAantibody
MAntibody × Deffector
(6)
Equation 6 is the mathematical expression of the declining curve
in Figure 3A. It also links the two Y scales in Figure 1 (PTAeffector
vs. MPTAantibody). Because antibody internalization continues
over time, the percent tumor accumulation of the effector may
decrease when a long pretargeting interval is used (Lollo et al.,
1994; Santos et al., 1995; Gautherot et al., 1998; Liu et al., 2005).
In other words, the saturation dosage of the effector at a shorter
pretargeting interval is larger than that at a longer pretargeting
interval. If the effector dosage is reduced to match the decreased
number of accessible secondary targets, the effector PTA at a
longer pretargeting interval would be back to itsMPTA (Equation
4). However, we should bear in mind that tumor growth during
the pretargeting interval may continues, that also contributes to
the reduced target number per gram of tumor. The target number
per gram of tumor in the equation is that at the time of effector
injection.
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The percent tumor accumulation (PTA) can be converted to
absolute tumor accumulation (ATA) by multiplying it by the
effector dosage Deffector :
ATAeffector
(
ng/g
)
=
Meffector × Dantibody × gpm × α× MPTAantibody
MAntibody
= constant (at Maximum) (7)
This explains Figure 3 in which, given an antibody dosage
(Dantibody), the absolute tumor accumulation of the effector (ATA)
at saturation dosages is a constant and at its maximum (referred
to as maximum absolute tumor accumulation, MATA). The
declining PTA curve in Figure 3A can then be mathematically
expressed in a simpler way by simplifying Equation 6 to:
PTA effcetor
(
%ID/g
)
=
MATAeffcetor (ng/g)
Deffector (ng)
× 100% (8)
Without this mathematical deduction, it is impossible to fit the
limited data in Figure 3A with this a declining curve.
The above reasoning also applies to direct targeting. As said,
in a blocking study with pre- or co-injection of the cold targeting
agent, it is well agreed that a reduced tumor accumulation would
suggest a specific binding. For a tumor targeting antibody, there
are documented reports showing reduced tumor accumulations
in human (Lamberts et al., 2015), but there are also many studies
showing unreduced tumor accumulation even at a very high
dosage. In this latter case, caution needs to be taken, because
unreduced percent tumor accumulation may be due to the large
number of the highly expressed antigens (Liu et al., 2005).
Independence of MPTA Ratio to Tumor Size
For a given tumor model at a given size in a given mouse
strain, because F, f, W, AUC, and E are all fixed, the tumor
accumulation (MPTA) is a constant. When tumor size varies,
agreeing to that widely observed (Moshakis et al., 1981; Siegel
et al., 1990; Sharkey et al., 2003b; Liu et al., 2008a), tumor
accumulation (MPTA) may also vary. Our observation with the
cMORF effector in a LS174T mouse tumor model pretargeted
with a MORF-antibody is consistent to the reports in literature
(Liu et al., 2009a). However, our surprising finding by further
examination of our data is that while tumor accumulations of
both the antibody and the labeled effector vary with the tumor
size (Figure 5), theirMPTA ratio is independent of the tumor size
and remains constant (in this case, 4.12).
Based on Equation 4, this constant MPTA ratio leads to a
constant E ratio because the F, f, andW are the same for the same
tumor and the AUC is not a function of tumor size:
MPTAantibody
MPTAcMORF
=
Eantibody
EcMORF
×
AUCantibody
AUCcMORF
(9)
Currently, tumor accumulation data for two different targeting
molecules exactly in the same tumors are very limited. Thus,
although very likely, whether the constantMPTA ratio of the two
targeting agents is a common feature is yet to be fully validated.
Normal Tissue Background in a
Pretargeting Setting
The signal strength (%ID/g of the effector) in normal tissues
reflects the total of the free effector and the effector bound to the
residual circulating pretargeting antibody:
Total effector level = free effector level
+antibody− bound effector (10)
Without use of a clearing agent, the residual antibody level at
the time of effector injection is appreciably high, though many
times lower than that in the tumor. Due to its easier accessibility
and lower level, the residual antibody is easily saturated. For all
established pretargeting systems, the free effector levels in normal
organs are very low after 1 h, while the level of circulating the
antibody-bound effector may be considerable. Because of being
distributed, it is not easy to be measured by imaging. We have
noticed it can be calculated from the blood signal that can be
measured by blood sampling (Liu et al., 2007a):
Total effector level = free effector level + blood level
× organ/blood ratio (11)
As shown in Table 1, after correcting the free effector using
equation 11, the organ to blood ratios of the antibody (or
the antibody-bound effector) are constant, despite the effector
levels (%ID/g) are very different from one study to another.
This antibody equilibrium has been later confirmed by other
researchers (Shah and Betts, 2013). Thus, except for the high free
effector level in kidneys where it is excreted, the effector levels in
other normal organs in a pretargeting setting can be calculated.
When using a clearing agent, the principle applies, except the
antibody-bound effector level is much lower. Equation 11 may
be also very useful in clinical investigations because it is harder to
measure the low normal tissue background by imaging.
OPTIMIZATION OF A PRETARGETING
REGIMEN
Any change in antibody dosage, pretargeting interval, effector
dosage, or detection time may lead to a different effector
biodistribution. Adding a clearing agent would introduce more
variables. Without a theoretical guide, a complete optimization
of these variables would be difficult, especially in the clinic
(Axworthy et al., 2000; Wu, 2001; Sharkey et al., 2003b; van
de Watering et al., 2014). However, with the above quantitative
relationships, the optimization becomes much easier (Liu and
Hnatowich, 2008).
Antibody Dosage
There is only a convenient but no optimal antibody dosage. To
diminish the influence of any possible low antigen expression
in normal tissues, the antibody dosage should not be very low,
though an antibody dosage beyond saturation of tumor antigens
is not recommended, because it will end up suboptimal T/NT
ratios of the antibody and thus T/NT ratios of the effector. Over-
dosaging seldom happen in human due to the large body weight.
Frontiers in Pharmacology | www.frontiersin.org 7 December 2018 | Volume 9 | Article 1476
Liu A Revisit to the Pretargeting Concept
FIGURE 5 | The contrast between (A) the MPTA of 111 In labeled CC49 (∼ 160 kDa) and (B) the MPTA of a small water-soluble 99mTc-cMORF (∼ 6 kDa) used in our
pretargeting strategy. The cMORF clears essentially in 0.5–1 h, while it takes days for CC49. CC49 shows 4-fold higher tumor accumulation due to its longer
circulation.
TABLE 1 | Percent levels (%ID/g) of 99mTc-MORF effector in blood and several normal organs at 3 h post its IV injection to pretargeted mice and the organ to blood ratios
of the antibody-bound effectora.
Organs Freeb Study 1c Study 2c Study 3c Study 4c Study 5d Study 7d Average
Blood 0.04 5.44 ± 1.07 5.20 ± 0.48 3.34 ± 1.03 3.10 ± 0.46 1.27 ± 0.17 0.93 ± 0.08
Liver 0.27 1.90 ± 0.24 1.93 ± 0.18 1.33 ± 0.11 1.23 ± 0.15 0.60 ± 0.05 0.54 ± 0.03
Liver/blood 0.30 0.32 0.32 0.31 0.27 0.30 0.31
Spleen 0.17 1.09 ± 0.26 0.94 ± 0.22 0.70 ± 0.12 0.63 ± 0.08 0.33 ± 0.06 0.29 ± 0.05
Spleen/blood 0.17 0.15 0.16 0.15 0.13 0.13 0.15
Lung 0.12 2.04 ± 0.42 1.95 ± 0.19 1.37 ± 0.24 1.20 ± 0.30 0.74 ± 0.16 0.41 ± 0.07
Lung/blood 0.36 0.35 0.48 0.35 0.50 0.33 0.40
Heart 0.06 1.23 ± 0.18 1.05 ± 0.07 0.75 ± 0.07 0.71 ± 0.20 0.30 ± 0.07 0.22 ± 0.03
Heart/blood 0.22 0.19 0.21 0.21 0.20 0.18 0.20
Muscle 0.03 0.49 ± 0.08 0.45 ± 0.04 0.42 ± 0.09 0.36 ± 0.04 0.19 ± 0.02 0.13 ± 0.02
Muscle/blood 0.09 0.08 0.12 0.11 0.13 0.11 0.11
aThe organ/blood ratios are calculated based on Equation 11. bThe biodistribution of the free 99mTc-MORF effector in non-pretargeted mice. c(Liu et al., 2004); d (Liu et al., 2005).
On the contrary, in a preclinical mouse study there is little chance
for a too low dosage. Most likely any low but tangible antibody
dosage would be usable in mice, but for a preclinical therapeutic
study, the antibody dosage needs to be higher to provide enough
secondary target sites to take a sufficiently high effector dosage
for effective therapy.
Pretargeting Interval and Dosage of the
Clearing Agent
Without a clearing agent, a longer wait (pretargeting interval)
provides a lower level of the residual circulating antibody and
higher T/NT ratios of the “accessible” antibody.We say accessible
because the internalized antibody is not visible to the effector.
The T/NT ratios of the accessible antibody defines or equals to
the achievable (optimal) T/NT ratios of the effector. Although
a longer pretargeting interval provides higher T/NT ratios, it
also renders more internalization and reduces the number of
accessible secondary targets. Thus, the time for effector injection
is dictated by the accessible T/NT ratios that are acceptable. Use
of a clearing agent would obviate the long wait and its injection
should be given when the antibody tumor accumulation is close
to the maximum. The dosage of the clearing agent needs to be
optimized to be just enough to clear the circulating antibody,
especially when the clearing agent shares the same secondary
target with the effector. More than needed would unnecessarily
consume some valuable secondary targets in the tumor. Because
the clearance is rapid, the time between injections of the clearing
agent and the effector injection is short.
Effector Dosage
Effector dosage needs to be optimized to match the number
of the accessible secondary targets in tumor. At the saturation
point, the T/NT effector ratios are optimal while still at the
MPTA. As the effector level after corrected for the free effector
by Equation 11 is that bound to the antibody, these optimal
T/NT effector ratios should be the T/NT ratios of the accessible
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secondary targets or the accessible antibody. Below saturation,
the T/NT effector ratios are suboptimal and are lower than the
T/NT ratios of the accessible secondary targets. In this case, the
residual secondary targets in normal tissues are saturated, but
the secondary targets in tumor are not. Above the saturation, the
extra effector getting into tumor will just pass by. In this case,
although the T/NT effector ratios will still be optimal, the tumor
accumulation (%ID/g) will be lower (not at theMPTA).
The saturation point can be measured pre-clinically using
an effector dosage escalation (Liu et al., 2005). One important
question is about the shiftability of effector dosage optimized on
one tumor model to another. As discussed above, we have some
experience on tumors of different size. The MPTA ratio of the
pretargeting agent to the effector is not changing although both
accumulations vary in size. If the internalization extent of the
pretargeting antibody, i.e., the fraction of the secondary targets
that are not internalized and still able to bind the effector in the
tumor (α), is similar, the constant MPTA ratio at the saturation
point (optimal dosage) can then be translated to an unchanged
optimal dosage ratio of the pretargeting agent to the effector,
based on Equation 6 at the saturation point in the form of:
MPTAeffector
MPTAantibody
=
Dantibody
Deffector
×
Meffector × gpm × α
MAntibody
(12)
Thus, although tumors at different size may have a different
pattern in vascularization and interstitial pressure (i.e., a pattern
with different blood flow fraction to tumor f, tumor weight
W, and tumor trapping efficiency E), the optimal dosage ratio
between pretargeting antibody and effector should be the same.
Better appreciating this reasoning can be achieved by considering
a vascularization pattern that induces a less accumulation of
the pretargeting antibody may probably proportionally reduce
the delivery of the effector. Similar reasoning may apply
to shifting a pretargeting system from one tumor model to
another (a different cell line with the same antigen using the
same antibody for pretargeting). However, at this time this
reasoning has never been verified in different tumor models
experimentally.
Optimization in human is more challenging because both
tumors and tumor hosts (the patients) are different. Nevertheless,
at least we expect the dosage ratio optimized from one subject
may likely be extended to another, if the following logic holds to
be true:
If patient variation could be viewed as tumor
model variation, based on Equation 9, our observation
(E∗AUC)antibody/(E
∗AUC)effector = constant should still be held
and the following would be true:
[
MPTAantibody
MPTAeffector
]
Patient 1
=
[
MPTAantibody
MPTAeffector
]
Patient 2
(13)
At the saturation point (optimal dosage ratio) and assuming
the antibody internalization (α) in different patients is the
same (
Meffector × gpm × α
MAntibody
will then be the same), combination of
Equations 12 and 13 provides:
[
Deffector
Dantibody
]
optimal for patient 1
=
[
Deffector
Dantibody
]
optimal for patient 2
(14)
Currently, the available data are not sufficient to confidently
support extrapolation of (E∗AUC)antibody/(E
∗AUC)effector =
constant among different patients. Very likely, the different
pharmacokinetics in different patients may generate different
AUCs. Fortunately, AUC is measurable and, if a difference is
found, a correction may be made. Also, the assumption of the
same extent of internalization needs to be validated. Thus, at
this time, Equation 14 may be considered only as a first-order
approximation. If the logic is later confirmed to be true, our
simple model would be demonstrated with a predicting power
once again.
Detection Time
For tumor therapy, detection time is not a factor although
biodistribution changes with it. Tumor pretargeting is not
appealing for diagnosis, due to the multiple injections but it
is meaningful for imaging-guided pretargeted immunotherapy.
Imaging may be performed at multiple time points to measure
the tumor radioactivity curve to estimate the radiation absorbed
dose to tumor. In this case, the concept of an optimal imaging
time is not applicable as well.
ADVANTAGES OF THE PRETARGETING
STRATEGY AND ITS UNACCOMPLISHED
MISSION
The most important advantage common to all the pretargeting
mechanisms is that they can be adapted to different tumor
antigens if a slow-internalizing antitumor agent is available. The
nature of different pretargeting mechanisms is the same and the
function of all the different recognition pairs is to convert the
natural primary antigens to an artificial secondary target specific
for a small effector. What differentiates different mechanisms
is their ease for technological improvements. For examples, the
immunogenicity of streptavidin has made its clinical application
more difficult (Larson et al., 2015); the versatility in labeling
an effector with both a diagnostic and a therapeutic nuclide
may enable a system for broader theranostic utility (Sharkey
et al., 2003b; Liu et al., 2009b); and an easier modulation
of the effector structure may offer an opportunity to tailor
its pharmacokinetics(Liu et al., 2002a,c; Meyer et al., 2017);
Their application to the clinic is common in combining with
other auxiliary measures for improved therapeutic effect. These
measures may include fractionated or multi-cycle therapy (Cheal
et al., 2016, 2017), better clearing agent (Cheal et al., 2014; Dou
et al., 2015), improved specific radioactivity (Liu et al., 2006), and
use of a different nuclide (Heskamp et al., 2017).
Another major advantage of pretargeting is its ability
to address the normal tissue background of directly-labeled
antibody. Natural clearance of the circulating antibody in
combination with the rapid clearance of the effector enables the
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high T/NT ratios compared to that of the directly radiolabeled
antibody (Goodwin, 1995). While the 2-step conventional
pretargeting greatly improves the T/NT ratios, the 3-step
pretargeting using a highly efficient clearing agent completely
fulfills the promise for a very low normal tissue background.
In addition to application to radioimmunotherapy, the high
T/NT signal ratios are also be potentially useful for detection of
sparsely-populated micro-organs such as islets in connection to
diabetes (Liu et al., 2011, 2012). Medical physics cannot delineate
themicrometer-sized pancreatic islets that account for only 1–2%
of the pancreas.
Although not often mentioned in the literature, an additional
advantage of pretargeting is the dramatic background reduction
and thus-improved the T/NT ratios in some normal organs. The
mechanism is the sequestration of the pretargeting antibody in
these organs. The small effector does not “see” the pretargeting
antibody extensively accumulated in the liver, and thus only
slightly accumulates in this organ (Liu et al., 2003, 2012). Similar
sequestration happens in the spleen and lung. Sequestration
also happens in the kidneys with some smaller tumor-targeting
proteins. Some directly radiolabeled proteins highly accumulate
in kidneys due to renal reabsorption. Nevertheless, by attaching
an effector-binding group to them and using them as the
pretargeting agents, the kidney accumulation of the effector
becomes lower (Westerlund et al., 2015, 2018; Honarvar et al.,
2016; Altai et al., 2017). Although the effector excretes through
this organ, it does not enter the compartment where the proteins
reside such that the kidney radioactivity accumulation is lower.
The multiple-injections for pretargeting are apparently
a disadvantage, but the high T/NT ratios are crucial for
radiotherapy (Larson et al., 2015; Liu, 2016). Of course, if both an
antibody and a small molecule are available for the same target,
like the prostate membrane specific antigen (PMSA) (Smith-
Jones et al., 2000, 2003; Sharkey, 2005; Haberkorn et al., 2017;
Kopka et al., 2017), and the directly labeled small targeting
molecule can achieve a similar success in terms of high T/NT
ratios, it would be preferable to use that small molecule due to the
single injection. However, in many cases antibody pretargeting
and small targeting molecules are not comparable, because
their primary targets are different. A small molecule targeting
agent for one target is not likely to be shifted to another
target. Developing a completely new small direct-targeting agent
requires the structure to bind the target strongly and at the same
time to clear from normal tissues rapidly. In contrast, applying an
established pretargeting system to a different antigen is so much
easier than developing a small targeting agent, just as Dr Sharkey
said, “the direct route may not be the best way to home” (Sharkey,
2005).
The non-internalization requirement of the antibody is
another constraint to pretargeting. Most antibodies internalize,
including the so-called non-internalizing antibodies. It is
fortunate in most cases a considerable percent of the pretargeting
molecules remain on the cell surface at the time of effector
injection. We have proved both theoretically and experimentally
that theMPTAeffector will not be compromised by use of different
antibodies and antibody internalization (Mirallié et al., 2005;
Liu et al., 2007b, 2010c). Recently other researchers have also
confirmed preclinically that internalizing antibodies can be used
for pretargeting (Sharkey et al., 2012b; Houghton et al., 2016).
We note this is not to say internalization is not a problem for
pretargeting. When developed into the clinical stage where the
pharmacokinetics of the antibody is slower than in mice, the
internalization issue may deteriorate to an extent that it becomes
impractical (Casalini et al., 1997).
An unaccomplished mission for pretargeting is to achieve a
high tumor accumulation that the pioneers have long hoped by
using a small effector (Goodwin, 1995). In the beginning, it was
thought a rapid targeting may provide a tumor accumulation
as high as that of the pretargeting antibody while generating
a low normal tissue background (Goodwin, 1995). Gradually it
becomes recognized that the targeting process of an effector is
nothing different to that of the small molecule direct-targeting
(Kopka et al., 2017). The rapid targeting can not compensate
the rapid clearance (Liu et al., 2009b; Goldenberg et al., 2012).
Currently, there is a paucity of investigations directly comparing
the tumor accumulations of an antibody with that of a small
effector in the same tumors as we did (Liu et al., 2005; Dou
et al., 2014b). There are studies comparing the iodine-labeled
antibodies with the metal-labeled effectors. Deiodination makes
an underestimated the tumor signal of the antibody (Axworthy
et al., 2000). Even so, the accumulation of the antibody is
double or triple higher. Sometimes tumor accumulation of an
effector can be very high, due to tumor model variation (van
Schaijk et al., 2005a,b), but effector tumor accumulation is still
several times lower than that of the antibody. It seems as if
we need a targeting agent that is “both large and small” to
have both the advantages of high tumor accumulation and
low background. Recently, there was a report suggesting small
molecules can achieve a tumor accumulation as high as that of
the antibodies (Orcutt et al., 2011; Wittrup et al., 2012), but
caution needs to be taken because the agent circulation and
excretion data are limited to a given class of molecules. The
experimental data continued to show the tumor accumulations
of small hydrophilic molecules are 3- times lower than that of the
IgG antibodies.
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